ClinicalTrials.gov
public full text
Public Domain
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
Omega 3 (OM3) Tear is a new unit dose emulsion, containing flaxseed/castor oil, which is being developed by Allergan. It is desirable to understand the effect that this new emulsion has on tear film evaporation and tear lipid profile via interferometry, in patients with evaporative dry eye (EDE) and those without (non-EDE). It would also be valuable to evaluate the retention time of the lipid components of the new emulsion via tear collection and analysis in EDE and non-EDE patients
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Placebo Controlled Double Masked Clinical Assessment Study of Essential Fatty Acid Supplement and Its Effect on Patients With Apparent Aqueous Deficient Dry Eye Syndrome#1164214
- Omega-3 Fatty Acid Supplementation and Tear Film Quality in Celiac Patients#1044209
- Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression#826658
- Evaluation of Human Efficacy for Skin Moisturization and Wrinkle Improvement#899806
- Clinical Trial to Evaluate the Efficacy of Skin Products to Improve Skin Quality and Health#1172279
Record · ID 1087119
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive